Sanofi and Owkin are expanding their collaboration on artificial intelligence, with a focus on developing ai agents for drug development and discovery. The initiative appears to be part of a broader effort to advance the use of ai in the life sciences. Details of the collaboration and its specific goals are not entirely clear, with some reports mentioning a focus on building drug development ai agents and others discussing the expansion of ai across life sciences innovation.